Clinics
Dapagliflozin as an adjunct to insulin improves glycemic control, weight, and lipid profile with a superior safety profile in type 2 diabetes: a randomized trial
Randomised trial in 86 peopleInterventions
3 months, declared no competing interests
- Dapagliflozin
- Lipid and ceramide metabolism
- Type 2 diabetes
- 2-hour postprandial glucose
- Body mass index
- Humans
The paper
Anhui University of Traditional Chinese Medicine; Beijing University of Chemical Technology
Clinics, 5 Sep 2026
